Startup Develops Blood-Purification Tech to Combat Pediatric Sepsis

A startup named Efferon is pioneering a new blood-purification technology with the ambitious goal of eradicating the devastating impact of pediatric sepsis. This innovative approach aims to directly address the life-threatening condition that affects hundreds of thousands of children globally each year.

The technology, developed by the Battlefield 200 startup, focuses on removing harmful pathogens and inflammatory mediators from the bloodstream. Pediatric sepsis is a complex and rapidly progressing illness that can lead to organ failure and death if not treated promptly. Efferon's innovation offers a potential new avenue for intervention, particularly for vulnerable young patients.